IGF1R and melanoma: When comparing treatment-naïve and dabrafenib- or vemurafenib-treated melanoma patients, Johnson et al. identified PI3K-AKT signaling and increased expression of PDGFRβ or insulin-like growth factor 1 receptor (IGF1R) as mechanisms of therapy resistance [78,99,106].